Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 1 Saturday Friday Sunday Monday Tuesday Publication Only FRIDAY, MAY 31 ST 2:45pm - 5:45pm Central Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 2:45 - 5:45pm 2:45 - 2:57pm S100bc Oral LBA6500 ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator- selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results. Hughes T Andorsky D Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant 2:45 - 4:15pm 2:51 - 2:57pm E451 Oral 511 Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline. O'Shaughnessy J O'Shaughnessy J, Osborne C Breast Cancer— Local/Regional/ Adjuvant 2:45 - 4:15pm 3:09 - 3:15pm E451 Oral 512 Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial. Yardley D Yardley D Breast Cancer— Local/Regional/ Adjuvant 2:45 - 5:45pm 3:45 - 3:57pm Arie Crown Theater Oral LBA8503 Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression- free survival and safety from the CROWN study. Solomon B Bauer T Lung Cancer—Non- Small Cell Metastatic 2:45 - 5:45pm 3:57 - 4:09pm S100bc Oral 6504 Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study. Jabbour E Shaughnessy P Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant 2:45 - 5:45pm 4:57 - 5:09pm Hall D1 Oral 9507 Phase 1 safety and efficacy of IMC- F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM). Hamid O Williams A, Sato T Melanoma/Skin Cancers 2:45 - 5:45pm 5:21 - 5:33pm Hall D1 Oral Discussant McKean M PD-1–Refractory Advanced Melanoma: How Do We Get to the Finish Line?